Michelle A Ingram1, M Beatrix Jones2, Welma Stonehouse3, Paul Jarrett4,5, Robert Scragg6, Owen Mugridge1, Pamela R von Hurst1. 1. a School of Sport, Exercise and Nutrition , Massey University, Albany Campus , North Shore City, Auckland , New Zealand. 2. b Institute of Natural and Mathematical Sciences, Massey University, Albany Campus , North Shore City, Auckland , New Zealand. 3. c Food and Nutrition Flagship , Commonwealth Scientific and Industrial Research Organisation , Adelaide, South Australia , Australia. 4. d Department of Dermatology , Middlemore Hospital , Otahuhu, Auckland , New Zealand. 5. e Department of Medicine , The University of Auckland , Auckland , New Zealand. 6. f School of Population Health , The University of Auckland , Auckland , New Zealand.
Abstract
PURPOSE: The management of psoriasis remains a challenge for dermatologist and patient. This study aimed to determine whether vitamin D3 supplementation improves psoriasis compared to placebo. MATERIALS AND METHODS: In a randomized, doubled-blind, placebo-controlled trial, 101 participants ≥18 years with psoriasis were grouped by severity and allocated to 100,000 International Units (IU) vitamin D3/month for 12 months (200,000 IU at baseline; n = 67) or an identical placebo (n = 34). Psoriasis Area and Severity Index (PASI) and serum25(OH)D concentrations were assessed at 3-monthly intervals. The primary outcome was the difference in PASI between groups over time. The relationship between 25(OH)D and PASI across the sample was also considered in a post hoc analysis. RESULTS:PASI did not differ between groups at any time (group F(1, 104) = 0.48, p = .49; group*time F(4, 384) = 0.26, p = .90). However, 25(OH)D increased in both groups, rendering these findings inconclusive. A significant inverse relationship existed between PASI and 25(OH)D, with elevation of 25(OH)D by up to 125 nmol/L associated with mild decreases in PASI (estimated range of decrease 0-2.6; p = .002). CONCLUSIONS: A direct benefit of vitamin D3 supplementation for psoriasis could not be determined. However, these findings suggest a relationship between 25(OH)D and psoriasis severity, at least in some subgroups. Australian New Zealand Clinical Trials Registry #12611000648921.
RCT Entities:
PURPOSE: The management of psoriasis remains a challenge for dermatologist and patient. This study aimed to determine whether vitamin D3 supplementation improves psoriasis compared to placebo. MATERIALS AND METHODS: In a randomized, doubled-blind, placebo-controlled trial, 101 participants ≥18 years with psoriasis were grouped by severity and allocated to 100,000 International Units (IU) vitamin D3/month for 12 months (200,000 IU at baseline; n = 67) or an identical placebo (n = 34). Psoriasis Area and Severity Index (PASI) and serum 25(OH)D concentrations were assessed at 3-monthly intervals. The primary outcome was the difference in PASI between groups over time. The relationship between 25(OH)D and PASI across the sample was also considered in a post hoc analysis. RESULTS: PASI did not differ between groups at any time (group F(1, 104) = 0.48, p = .49; group*time F(4, 384) = 0.26, p = .90). However, 25(OH)D increased in both groups, rendering these findings inconclusive. A significant inverse relationship existed between PASI and 25(OH)D, with elevation of 25(OH)D by up to 125 nmol/L associated with mild decreases in PASI (estimated range of decrease 0-2.6; p = .002). CONCLUSIONS: A direct benefit of vitamin D3 supplementation for psoriasis could not be determined. However, these findings suggest a relationship between 25(OH)D and psoriasis severity, at least in some subgroups. Australian New Zealand Clinical Trials Registry #12611000648921.
Authors: Anna A Brożyna; Michał A Żmijewski; Kinga Linowiecka; Tae-Kang Kim; Radomir M Slominski; Andrzej T Slominski Journal: Exp Dermatol Date: 2022-01-13 Impact factor: 4.511
Authors: Anna A Brożyna; Radomir M Slominski; Bogusław Nedoszytko; Michal A Zmijewski; Andrzej T Slominski Journal: Int J Mol Sci Date: 2022-08-02 Impact factor: 6.208